	Application No.	Applicant(s)
	09/848,780	SANDERS, MITCHELL C.
Notice of Allowability	Examiner	Art Unit
	Samuel W Liu	1653
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-88 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENTS of the Office or upon petition by the applicant. See 37 CFR 1.37	S (OR REMAINS) CLOSED i 5) or other appropriate comm RIGHTS. This application is	n this application. If not included unication will be mailed in due course. <b>THIS</b>
1. $\boxtimes$ This communication is responsive to <u>2-17-04 &amp; 4-11-03</u> .		
2. The allowed claim(s) is/are <u>6-15</u> .		
3. $\boxtimes$ The drawings filed on <u>03 May 2001</u> are accepted by the l	Examiner.	
4. Acknowledgment is made of a claim for foreign priority (a) All b) Some* c) None of the:  1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have 1. Certified copies of the priority documents have 2. Certified copies of the certified copies of the priority documents have 3. Certified copies of the certified copies of the priority documents have 2. Certified copies not received:	ve been received. ve been received in Applicati	on No
Applicant has THREE MONTHS FROM THE "MAILING DATE noted below. Failure to timely comply will result in ABANDON THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		e a reply complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be sub INFORMAL PATENT APPLICATION (PTO-152) which gi		
6. CORRECTED DRAWINGS (as "replacement sheets") m	ust be submitted.	
(a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
<ul><li>(b) ☐ including changes required by the attached Examine Paper No./Mail Date</li></ul>	er's Amendment / Comment o	or in the Office action of
Identifying indicia such as the application number (see 37 CFR each sheet. Replacement sheet(s) should be labeled as such in	1.84(c)) should be written on the header according to 37 C	the drawings in the front (not the back) of FR 1.121(d).
7. DEPOSIT OF and/or INFORMATION about the department attached Examiner's comment regarding REQUIREMENT	osit of BIOLOGICAL MAT	ERIAL must be submitted. Note the
Attachment(s)  1. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SE Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	) 6. ⊠ Interview S Paper No 3/08), 7. ⊠ Examiner's	nformal Patent Application (PTO-152) Summary (PTO-413), ./Mail Date <u>3-10-04</u> . s Amendment/Comment s Statement of Reasons for Allowance

Art Unit: 1653

## **DETAILED ACTION**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on February 17, 2004 has been entered.

This Office action is in response to (i) applicants' amendments filed 17 February 2004 which amends claims 6-15; and (ii) applicants' amendement filed 11 April 2003, which cancels claims 1-5 and adds claims 6-15. The amendments indicated above have been entered. The pending claims 6-15 are therefore examined in this Office action.

## **EXAMINER'S AMENDMENT**

An Examiner's Amendment to the record appears below. Should the change and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no latter than payment of the Issue Fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Deirdre E. Sanders on March 10, 2004.

## Amendments to the specification:

In page 4, line 16, change "SDS PAGE" to "SDS polyacrylamide gel electrophoresis (SDS PAGE)".

In page 5, line 20, change "37-C" to "37 °C".

In page 7, line 5, change "p26-RSET C, p26-pPE21" to "p26-RSET C and p26-pPE21".

In page 7, line 20, change "thepKK223-3" to "the pKK223-3".

## Amendments to the specification:

Page 3

The pending claims 8-9 and 11-12 have been amended as follows. Please replace the previous claims with the claims shown below.

Claim 8 (twice amendment): after "comprises said alpha-crystallin type protein or a fragment thereof" add "that has an ability of improving stability and solubility of said insoluble protein"; and after "between said alpha-crystallin type protein or a fragment thereof" add "that has an ability of improving stability and solubility of said insoluble protein".

Claim 9 (twice amendment): delete ", said method" after "a first protein"; and add "that has an ability of increasing the solubility of said first protein" after "a fragment thereof".

Claim 11 (twice amendment): add "that has an ability of increasing the solubility of said first protein" after "comprises said alpha-crystallin type protein or a fragment thereof"; and add "that has an ability of increasing the solubility of said first protein" after "between said alphacrystallin type protein or a fragment thereof a fragment thereof".

Claim 12 (twice amendment): add "a" before "fragment thereof"; and add "that has an ability of increasing the stability of said first protein" after "fragment thereof".

Conclusion: claims 6-15 are allowable over the art of record.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Samuel Wei Liu, Ph.D. whose telephone number is (571) 272-0949. The Examiner can normally be reached daily except alternate Fridays from 8:30 A.M. to 5:30 P.M. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Christopher Low, can be reached at (571) 272-0951. The official fax number for Technology Center 1600 is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology Center 1600 receptionist whose telephone number is (703) Jan-Ca han Carlsai (Pa) 308-0196.

-500 L

Samuel W. Liu, Ph.D.

March 10, 2004

KAREN COCHRANE CARLSON, PH.D.